Radiomics- based biomarkers for immunotherapy in non-small cell lung cancer: advances, challenges, and future perspectives in biological interpretation and clinical translation
Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet treatment benefit remains heterogeneous and resistance is common. Genomic alterations, tumor microenvironment (TME) remodeling, and metabolic reprogramming across spatial and temporal scales that are incompletely cap...